An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
出版年份 2019 全文链接
标题
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 18, Issue 8, Pages 691-701
出版商
Informa UK Limited
发表日期
2019-06-01
DOI
10.1080/14740338.2019.1626823
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Fracture Risk After Initiation of Use of Canagliflozin
- (2019) Michael Fralick et al. ANNALS OF INTERNAL MEDICINE
- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
- (2019) Darren K. McGuire et al. CIRCULATION
- Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes
- (2019) Seon Gu Lee et al. JAMA Dermatology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
- (2018) Stephen D. Wiviott et al. AMERICAN HEART JOURNAL
- Cardiovascular Effects of New Oral Glucose-Lowering Agents
- (2018) André J. Scheen CIRCULATION RESEARCH
- Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis
- (2018) B.M. Mishriky et al. DIABETES & METABOLISM
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER
- (2018) Patrick B. Ryan et al. DIABETES OBESITY & METABOLISM
- SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
- (2018) Charles Khouri et al. DIABETES OBESITY & METABOLISM
- Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03)
- (2018) Ritsuko Yamamoto-Honda et al. INTERNAL MEDICINE
- Japanese Clinical Practice Guideline for Diabetes 2016
- (2018) Masakazu Haneda et al. Journal of Diabetes Investigation
- Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
- (2018) Lana C. Pinto et al. Scientific Reports
- Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
- (2018) Devin Abrahami et al. BMJ-British Medical Journal
- Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
- (2018) Devin Abrahami et al. BMJ-British Medical Journal
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
- (2018) Christopher P. Cannon et al. AMERICAN HEART JOURNAL
- Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes
- (2018) Khalaf Kridin et al. JAMA Dermatology
- Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
- (2018) A.J. Scheen DIABETES & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus
- (2017) Takahiro Kambara et al. Geriatrics & Gerontology International
- Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype
- (2017) Lee Ling Lim et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing
- (2017) Gisela Schott et al. BMC Geriatrics
- The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials
- (2017) Jun Yang et al. PLoS One
- Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study
- (2016) Huang-Tz Ou et al. Cardiovascular Diabetology
- Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes
- (2016) Ivan Tkáč et al. DIABETES CARE
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial
- (2016) William B. White et al. DIABETES CARE
- Pancreatic Safety of Sitagliptin in the TECOS Study
- (2016) John B. Buse et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- SGLT2 Inhibitors and the Diabetic Kidney
- (2016) Paola Fioretto et al. DIABETES CARE
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – A systematic review and meta-analysis
- (2016) Jil Mamza et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis
- (2016) Se Hee Min et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases
- (2016) Annamaria Mascolo et al. DRUG SAFETY
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives
- (2016) Yutaka Seino et al. Journal of Diabetes Investigation
- Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
- (2016) Young-Gun Kim et al. Journal of Diabetes Research
- Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
- (2016) Laurent Azoulay et al. JAMA Internal Medicine
- Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
- (2016) Jianying Fu et al. Scientific Reports
- Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials
- (2015) A. S. Abbas et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis
- (2015) Gianluigi Savarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
- (2015) K. Esposito et al. BMJ Open
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
- (2014) Kohei Kaku et al. Cardiovascular Diabetology
- Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
- (2014) Nayyar Iqbal et al. Cardiovascular Diabetology
- Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants
- (2014) Shiying Wu et al. Cardiovascular Therapeutics
- Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis
- (2014) Y. G. Kim et al. DIABETES OBESITY & METABOLISM
- Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database
- (2014) Jianping Weng et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
- (2014) Daisuke Yabe et al. Journal of Diabetes Investigation
- Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response: A systematic review and meta-analysis
- (2013) K. Kodama et al. DIABETES CARE
- Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
- (2013) W. B. White et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
- (2013) S. Macha et al. DIABETES OBESITY & METABOLISM
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
- (2013) Y. G. Kim et al. DIABETOLOGIA
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Higher insulin and glucagon-like peptide-1 (GLP-1) levels in healthy, young South Asians as compared to Caucasians during an oral glucose tolerance test
- (2013) Maria A. Sleddering et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes
- (2013) André J. Scheen POSTGRADUATE MEDICINE
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- A review of the efficacy and safety of oral antidiabetic drugs
- (2012) Stephanie Aleskow Stein et al. Expert Opinion On Drug Safety
- Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels
- (2012) Masahiro Iwasaki et al. Journal of Diabetes Investigation
- A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes
- (2011) Valerie Hutchins et al. CURRENT MEDICAL RESEARCH AND OPINION
- Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
- (2011) M. Monami et al. DIABETES CARE
- Exendin-4 Suppresses Src Activation and Reactive Oxygen Species Production in Diabetic Goto-Kakizaki Rat Islets in an Epac-Dependent Manner
- (2010) E. Mukai et al. DIABETES
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Obesity-related non-communicable diseases: South Asians vs White Caucasians
- (2010) A Misra et al. INTERNATIONAL JOURNAL OF OBESITY
- Fixed-dose single tablet antidiabetic combinations
- (2009) C. J. Bailey et al. DIABETES OBESITY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now